Rayze Bio
San Diego, US · Founded 2020 · Delaware corporation · 8 known investors
RayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.
Founders & leadership
BH
Ben HickeyPresident
AB
Abhi Bhat, PhDSenior Vice President, Research & Development
DC
Deborah CharychExecutive Officer
JD
Jerel DavisDirector
KS
Ken SongExecutive Officer, Director
BK
Bong KohDirector
AK
Aaron KantoffDirector
YL
Yi LarsonDirector
AR
Aaron RoystonDirector
Investors · 8
Samsara BioCapitalPalo Alto
Scion Life SciencesNew York · $1K – $60M
Sofinnova VenturesMenlo Park · $100K – $15M
TCG CrossoverPalo Alto
venBio PartnersSan Franciscovia Aaron Royston · board
Versant VenturesSan Francisco · $250K – $5M
Vivo CapitalPalo Alto · $10M – $50M
venBio Global StrategicreportedSan Francisco
Reported raises · per SEC filings
Form D private placements▶$167.9MraisedSep 2022 · 18 investors · BiotechnologyRule 506(b)
▶$167.9MraisedSep 2022 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron KantoffDirector
- Angie YouDirector
- Aaron RoystonDirector
- Yi LarsonDirector
- Aubrey HaddachExecutive Officer
- Mary TagliaferriDirector
- Jerel DavisDirector
- Ken SongExecutive Officer, Director
- Arvind KushExecutive Officer
- Maha KatabiDirector
- Alex RosenDirector
- Offering amount
- $167.9M
- Amount sold
- $167.9M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$108.5MraisedJun 2021 · 23 investors · BiotechnologyRule 506(b)
▶$108.5MraisedJun 2021 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Deborah CharychExecutive Officer
- Aaron RoystonDirector
- Jerel DavisDirector
- Ken SongExecutive Officer, Director
- Bong KohDirector
- Aaron KantoffDirector
- Yi LarsonDirector
- Offering amount
- $108.5M
- Amount sold
- $108.5M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$105MraisedDec 2020 · 17 investors · BiotechnologyRule 506(b)
▶$105MraisedDec 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bong KohDirector
- Ken SongExecutive Officer, Director
- Aaron KantoffDirector
- Jerel DavisDirector
- Aaron RoystonDirector
- Offering amount
- $105M
- Amount sold
- $105M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$15MraisedNov 2020 · 9 investors · BiotechnologyRule 506(b)
▶$15MraisedNov 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron RoystonDirector
- Jerel DavisDirector
- Aaron KantoffDirector
- Ken SongExecutive Officer, Director
- Offering amount
- $45M
- Amount sold
- $15M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.